These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1409329)

  • 1. Immune response to gp120 of HIV: antibody spectrotype and inhibitory activity on T cell functions.
    Aiuti F; Pontesilli O; Biselli R; Matricardi PM; Lovigu C; Carlesimo M; Nisini R; Mezzaroma I; Pinter E; Varani AR
    Pharmacol Res; 1992 Sep; 26 Suppl 2():64-5. PubMed ID: 1409329
    [No Abstract]   [Full Text] [Related]  

  • 2. Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease.
    D'Amelio R; Biselli R; Nisini R; Matricardi PM; Aiuti A; Mezzaroma I; Pinter E; Pontesilli O; Aiuti F
    J Acquir Immune Defic Syndr (1988); 1992; 5(9):930-5. PubMed ID: 1512693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS vaccines: back to 'plan A'.
    Check E
    Nature; 2003 Jun; 423(6943):912-4. PubMed ID: 12827164
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
    Moore JP; Ho DD
    AIDS; 1995; 9 Suppl A():S117-36. PubMed ID: 8819579
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
    Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An HIV vaccine--evolving concepts.
    Johnston MI; Fauci AS
    N Engl J Med; 2007 May; 356(20):2073-81. PubMed ID: 17507706
    [No Abstract]   [Full Text] [Related]  

  • 7. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination effect on HIV infection in vitro of soluble CD4 and HIV-neutralizing antibodies.
    Hansen JE; Sørensen AM; Olofsson S; Osinaga E; Roseto A
    Arch Virol; 1994; 134(1-2):179-84. PubMed ID: 8279954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells.
    de Santis C; Lopalco L; Robbioni P; Longhi R; Rappocciolo G; Siccardi AG; Beretta A
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):157-62. PubMed ID: 7515259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation.
    Mittler RS; Hoffmann MK
    Science; 1989 Sep; 245(4924):1380-2. PubMed ID: 2571187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific cytolysis of HIV-infected cells by lymphocytes armed with bifunctional antibodies.
    Okada H; Momota H; Azuma T; Hattori T; Okada N
    Immunol Lett; 1992 Feb; 31(3):247-52. PubMed ID: 1532163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients.
    Silvestris F; Nagata S; Cafforio P; Silvestris N; Dammacco F
    J Exp Med; 1996 Dec; 184(6):2287-300. PubMed ID: 8976184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of HIV-1 V3 serotyping in studying the HIV-1 epidemic in South Africa.
    Cheingsong-Popov R; Williamson C; Lister S; Morris L; van Harmelen J; Bredell H; Wood R; Sonnenberg P; van der Ryst E; Martin D; Weber J
    AIDS; 1998 May; 12(8):949-50. PubMed ID: 9631149
    [No Abstract]   [Full Text] [Related]  

  • 14. Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies.
    Nishiyama Y; Karle S; Mitsuda Y; Taguchi H; Planque S; Salas M; Hanson C; Paul S
    J Mol Recognit; 2006; 19(5):423-31. PubMed ID: 16838382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of primates with native, recombinant HIV-SF2 gp120 generates broadly effective neutralizing antibodies directed to conformational epitopes.
    Steimer KS; Haigwood NL
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1391. PubMed ID: 1281658
    [No Abstract]   [Full Text] [Related]  

  • 16. Diversity and variation in human immunodeficiency virus: implications for immune control.
    Ramsay AJ
    Immunol Cell Biol; 1992 Jun; 70 ( Pt 3)():215-21. PubMed ID: 1452223
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.
    Hioe CE; Jones GJ; Rees AD; Ratto-Kim S; Birx D; Münz C; Gorny MK; Tuen M; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2000 Jun; 16(9):893-905. PubMed ID: 10875615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation.
    Chien PC; Chen D; Chen PD; Tuen M; Cohen S; Migueles SA; Connors M; Rosenberg E; Malhotra U; Gonzalez C; Hioe CE
    J Infect Dis; 2004 Mar; 189(5):852-61. PubMed ID: 14976603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of T lymphocytes in human CD4 transgenic mice induced by HIV-gp120 and gp120-specific antibodies from AIDS patients.
    Wang ZQ; Orlikowsky T; Dudhane A; Mittler R; Blum M; Lacy E; Riethmüller G; Hoffmann MK
    Eur J Immunol; 1994 Jul; 24(7):1553-7. PubMed ID: 7913036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.